Researchers have identified specific strains of bacteria in the microbiome that are linked to a positive response to combination immunotherapy in various cancers, including rare gynecological and biliary tract cancers. A study published in Nature Medicine details how understanding the microbiome at a strain-level can help predict who will benefit from immunotherapy. The research used a machine-learning model to predict treatment response based on gut microbiota signatures. The findings suggest that tailoring therapeutics to the gut microbiome may improve cancer treatment effectiveness and reduce unnecessary side effects. This personalized approach could lead to the development of next-generation probiotics to support immunotherapy.
Source link
Microbial signatures linked to immunotherapy response across cancers
